INVESTMENT

Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 8, 2024 - 02:00
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Read More

Tags:

Previous Article

Autopsy suggests tycoon Mike Lynch likely died of suffocation in yacht - source

Next Article

Typhoon Yagi hits north Vietnam killing two and closing airports

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Apple wins $250 from Masimo in watch patent trial

Apple wins $250 from Masimo in watch patent trial

Tomas Kauer - Mode... Oct 27, 2024

European cyber insurance startup Stoïk secures $27M

European cyber insurance startup Stoïk secures $27M

Tomas Kauer - Mode... Oct 15, 2024

OpenAI 2024 event: How to watch new ChatGPT product reveals and demos

OpenAI 2024 event: How to watch new ChatGPT product rev...

Tomas Kauer - Mode... Dec 6, 2024